- RBC Capital upgrades Insmed (NASDAQ:INSM) to “Outperform” with a new price target of $138 following FDA approval of Brinsupri.
- Brinsupri, a treatment for non-cystic fibrosis bronchiectasis (NCFB), shows significant efficacy in Phase 3 and Phase 2 studies, highlighting its market potential.
- Insmed’s stock price hits a yearly high of $122.01, reflecting positive investor sentiment and the company’s strong market capitalization of approximately $25.79 billion.
On August 12, 2025, RBC Capital upgraded Insmed (NASDAQ:INSM) to “Outperform,” with the stock priced at $122. RBC Capital also raised its price target from $120 to $138. Insmed is a biopharmaceutical company focused on developing therapies for serious diseases, and this upgrade reflects positive market sentiment.
The FDA’s approval of Insmed’s drug, Brinsupri, is a significant milestone. Brinsupri is the first treatment for non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease affecting about 500,000 people in the U.S. This approval likely contributed to RBC Capital’s decision to upgrade Insmed’s stock rating.
Brinsupri’s approval is based on successful Phase 3 ASPEN and Phase 2 WILLOW studies. The ASPEN study showed a reduction in annual exacerbations by 21.1% for the 10 mg dosage and 19.4% for the 25 mg dosage compared to a placebo. This data underscores the drug’s effectiveness and potential market impact.
The stock’s current price of $122 represents an 8.07% increase, with a $9.11 change. It has fluctuated between $112.48 and $122.01 today, marking its highest price in the past year. The lowest price in the past year was $60.40, indicating significant growth.
Insmed’s market capitalization is approximately $25.79 billion, with a trading volume of 7,193,258 shares today. The company’s recent achievements, including Brinsupri’s approval, are likely driving investor interest and stock performance.
